Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SGMS2 | Q8NHU3 | 4/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092227 | 0.91 | HTR2C (0.44) | HTR2CHTR2BSGMS2CXCR1CXCR2 | |
| SCHEMBL6092190 | 0.84 | BUB1 (0.47) | HTR2CSGMS2RAB9A | |
| SCHEMBL6095988 | 0.83 | BRD4 (0.45) | SGMS2BRD4LRRK2MET | |
| SCHEMBL7386449 | 0.83 | ALDH1A1 (0.48) | RAB9A | |
| SCHEMBL6094319 | 0.82 | HTR2C (0.40) | HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL6093261 | 0.82 | BRD4 (0.44) | SGMS2BRD4LRRK2MET | |
| SCHEMBL8251851 | 0.82 | HTR2C (0.43) | HTR2CCXCR1CXCR2 | |
| SCHEMBL6110572 | 0.82 | HTR2C (0.42) | HTR2CHTR2BRAB9A | |
| SCHEMBL6094134 | 0.81 | BRD4 (0.43) | SGMS2BRD4LRRK2MET | |
| SCHEMBL8584124 | 0.81 | KMT2A (0.45) | HTR2CRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | disclosed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | HTR2C 261/4885HTR2B 153/4885SGMS2 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.